![](https://www.texasretina.com/wp-content/uploads/2022/06/Abbey-Ashkan-08-Blog-Head-Shot-1.jpg)
Posted On August 2, 2024 /
By Debbie Muse / Posted in Blog
Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read more